Hereditary spherocytosis screening: Difference between revisions

Jump to navigation Jump to search
Anthony Gallo (talk | contribs)
m Template
Amar Morani (talk | contribs)
Line 8: Line 8:


==Screening==
==Screening==
'''Prenatal testing, family testing, and genetic counseling''' —
* For young patients with HS, we obtain a full family history and obtain a CBC, reticulocyte count, and examination of the peripheral blood smear on each parent and sibling in order to determine whether the spherocytic mutation is dominant or recessive. Appropriate counseling can be performed once this information has been obtained. It is especially important to test a newborn sibling for HS, as this may be associated with severe degrees of hyperbilirubinemia and anemia during this period.
* For individuals of childbearing age with HS, review of the familial mutation and its mode of transmission (autosomal dominant or recessive) may be useful for informing discussions of the likelihood of HS in children. If the familial mutation is known to act in an autosomal dominant fashion, it is important to make this information clear in the prenatal record and to make the information available to the pediatrician before delivery [83]. Some individuals who had HS as a child and were treated with splenectomy may have forgotten about the condition or may not realize the implications for their child.
* It is also important to test newborns of affected parents for HS, as affected newborns may have severe hyperbilirubinemia and anemia. This may be done by a clinician with expertise in hemolytic anemias or by a genetic counselor. It is possible for an individual with no hemolysis, no spherocytes on the blood smear, and a normal reticulocyte count to be a carrier of HS, which may be relevant in certain families


==References==
==References==

Revision as of 12:32, 27 July 2018

Hereditary spherocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hereditary spherocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hereditary spherocytosis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hereditary spherocytosis screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hereditary spherocytosis screening

CDC on Hereditary spherocytosis screening

Hereditary spherocytosis screening in the news

Blogs on Hereditary spherocytosis screening

Directions to Hospitals Treating Hereditary spherocytosis

Risk calculators and risk factors for Hereditary spherocytosis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Screening

Prenatal testing, family testing, and genetic counseling

  • For young patients with HS, we obtain a full family history and obtain a CBC, reticulocyte count, and examination of the peripheral blood smear on each parent and sibling in order to determine whether the spherocytic mutation is dominant or recessive. Appropriate counseling can be performed once this information has been obtained. It is especially important to test a newborn sibling for HS, as this may be associated with severe degrees of hyperbilirubinemia and anemia during this period.
  • For individuals of childbearing age with HS, review of the familial mutation and its mode of transmission (autosomal dominant or recessive) may be useful for informing discussions of the likelihood of HS in children. If the familial mutation is known to act in an autosomal dominant fashion, it is important to make this information clear in the prenatal record and to make the information available to the pediatrician before delivery [83]. Some individuals who had HS as a child and were treated with splenectomy may have forgotten about the condition or may not realize the implications for their child.
  • It is also important to test newborns of affected parents for HS, as affected newborns may have severe hyperbilirubinemia and anemia. This may be done by a clinician with expertise in hemolytic anemias or by a genetic counselor. It is possible for an individual with no hemolysis, no spherocytes on the blood smear, and a normal reticulocyte count to be a carrier of HS, which may be relevant in certain families

References

Template:WS Template:WH